Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada

Suven Life Sciences, a clinical stage biopharmaceutical company discovering and developing novel medicines to treat Central Nervous System (CNS) disorders, today announced completion of enrollment for its phase-2 PoC clinical study evaluating the safety and efficacy of samelisant in adult narcolepsy patients with and without cataplexy. Data readout for the study is anticipated in second quarter of FY2024.

"We are pleased to have achieved this milestone with the development of samelisant in the narcolepsy space and look forward to the data readout in second quarter of FY2024". "Narcolepsy is a chronic disease characterized by the symptoms such as excessive daytime sleepiness (EDS) and cataplexy that impairs quality of life, Samelisant's mechanism of action increases histamine transmission in the brain which provides the scientific rationale for its potential clinical utility for the management of narcolepsy", said Mr. Venkat Jasti, Chairman & CEO of Suven Life Sciences.

Shares of Suven Life Sciences Limited was last trading in BSE at Rs. 56.32 as compared to the previous close of Rs. 56.94. The total number of shares traded during the day was 5562 in over 129 trades.

The stock hit an intraday high of Rs. 57.68 and intraday low of 56.11. The net turnover during the day was Rs. 315212.00.

Source : Equity Bulls

Keywords

SuvenLifeSciences INE495B01038 ENrollment Phase2 PoC ClinicalStudy Samelisant CNSDisorders